Status:
COMPLETED
Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Seasonal Allergic Rhinitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.
Eligibility Criteria
Inclusion
- Subjects 18 to 65 years of age with a positive skin prick test with ragweed allergen
Exclusion
- No active respiratory tract infection
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT01222299
Start Date
May 1 2010
End Date
August 1 2010
Last Update
October 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ISTA Pharmaceuticals, Inc.
Irvine, California, United States, 92618